Ixabepilone-Induced Delirium-Reference-Cited by-同舟云学术

Ixabepilone-Induced Delirium

Published:2024-09 Issue:5 Volume:31 Page:e556-e557
ISSN:1075-2765
Container-title:American Journal of Therapeutics
language:en
Short-container-title:

Author:

Yang Tzu-Ching¹²,Yeh Yi-Wei²,Wan Fang-Jung²,Huang Tzu-Chuan³,Lai Shiue-Wei³,Tzeng Nian-Sheng²⁴^ORCID

Affiliation:

1. Department of Psychiatry, Tri-Service General Hospital, Beitou Branch, National Defense Medical Center, Taipei, Taiwan;

2. Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan;

3. Division of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan; and

4. Student Counseling Center, National Defense Medical Center, Taipei, Taiwan e-mails: Tzu-Ching Yang, MD: chriswind27@gmail.com.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference9 articles.

1. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit;Ely;JAMA,2004

2. Association of hypoactive and hyperactive delirium with cognitive function after critical illness;Hayhurst;Crit Care Med,2020

3. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine;Perez;J Clin Oncol,2007

4. A method for estimating the probability of adverse drug reactions;Naranjo;Clin Pharmacol Ther,1981

5. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy;Roché;J Clin Oncol,2007